Immunomodulatory Effects of Hemagglutinin- (HA-) Modified A20 B-Cell Lymphoma Expanded as a Brain Tumor on Adoptively Transferred HA-Specific CD4+ T Cells
Figure 4
Response of HA-specific CD4+Thy-1.1+ T cells from cervical lymph nodes of A20HA brain tumor-bearing mice to HA peptide in vitro is reduced in process of the tumor progression and controversial to response of CD4+ T cells from spleen. ((a), (b)) Percent of CD4+Thy-1.1+ T cells (upper) and intensity of CD44 expression (lower) by cells isolated from (a) cervical lymph nodes and (b) spleens on days 2, 9, and 16 after the adoptive transfer. HA-specific CD4+Thy1.1+ T cells were injected i.v. into A20HA brain tumor-bearing mice 5 days after i.c. tumor inoculation (A20HA + T cells) and tumor-free control mice (T cells). A20HA brain tumor-bearing mice in the absence of HA-specific CD4+Thy1.1+ T cells represented a negative control (background staining of a specified area was lesser than 0.01%; data not shown). Cervical lymph nodes and spleens were pooled and analyzed by FACS for CD4+Thy1.1+CD44+ T cells before incubation and after 72 h incubation without (w/o) and with HA peptide. FACS data are presented as a percent of double positive cells, CD4 versus Thy1.1, and the level of CD44 expression in the CD4+Thy1.1+ T-cell population. One representative experiment of equivalent two is shown. .
